Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T12:55:28.641Z.
Calculation as of: 2026-10-06T12:55:28.641Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3a5f53e60080e4c0bd8028294acadec9828b96594dd07725d589d3e2217ece04
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Allogene Therapeutics, Inc.
Market Cap
$517.73M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$517.79M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$519.25M
Free Cash Flow Yield
N/A
TTM Avg
536.25%
3Y Avg
536.25%
5Y Avg
536.25%
Market Cap
$491.55M
Free Cash Flow Yield
N/A
TTM Avg
3.29%
3Y Avg
4.78%
5Y Avg
5.98%
Market Cap
$547.86M
Free Cash Flow Yield
3.20%
TTM Avg
3.62%
3Y Avg
3.23%
5Y Avg
3.23%
Market Cap
$487.30M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$551.09M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$481.33M
Free Cash Flow Yield
N/A
TTM Avg
18.77%
3Y Avg
18.69%
5Y Avg
14.04%
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | $517.73M | N/A | N/A | N/A | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $517.79M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $519.25M | N/A | 536.25% | 536.25% | 536.25% |
| Evolus, Inc. (EOLS)vs › | $491.93M | N/A | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $491.55M | N/A | 3.29% | 4.78% | 5.98% |
| Delcath Systems, Inc. (DCTH)vs › | $547.86M | 3.20% | 3.62% | 3.23% | 3.23% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $487.30M | N/A | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $551.09M | N/A | N/A | N/A | N/A |
| Arvinas, Inc. (ARVN)vs › | $481.33M | N/A | 18.77% | 18.69% | 14.04% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $478.54M | N/A | 3.93% | 3.93% | 3.93% |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
